Assessing the Global Burden of IgA Nephropathy (IgAN) in Patients Receiving Hemodialysis: A Real-World Study Using DOPPS Data

Arbor Research Collaborative for Health70,000 enrolled

Overview

This study leverages the global Dialysis Outcomes and Practice Patterns Study (DOPPS) database to generate real-world evidence on the burden of IgAN in patients who progress to kidney failure and require maintenance hemodialysis (HD). We will first aim to understand prevalence of IgAN in a global cohort of in-center HD patients. The second and third objectives aim to quantify the patient burden of IgAN using a two-step approach: first, a detailed single-arm evaluation of outcomes within the IgAN population; second, a matched comparison to the broader HD population.

Study Type

OBSERVATIONAL

Enrollment

70,000

Conditions

IgAN - IgA Nephropathy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Age ≥ 18 years at the time of enrollment * Receiving in-center HD treatment at a participating dialysis facility * Able to provide informed consent, if required by local regulations or ethics boards Exclusion Criteria: \-

Outcomes

Primary Outcomes

IgAN

Time frame: 1996-2023

Data from ClinicalTrials.gov